Pomerantz Law Firm Launches Investigation into Soleno Therapeutics for Investor Concerns

Investor Alert: Pomerantz Law Firm Investigates Soleno Therapeutics

Pomerantz LLP, a leading law firm in the field of securities class actions, has announced its investigation into Soleno Therapeutics, Inc., listed on NASDAQ under the ticker SLNO. This inquiry is focused on allegations that certain officers and directors of the company might have engaged in fraudulent activities or other illegal business operations. Investors are encouraged to reach out to the firm for more information regarding potential claims.

Background of the Investigation

The probe stems from a report released by Scorpion Capital on August 15, 2025, which critiques Soleno's flagship product, Vykat XR. The report states that Vykat XR, designed for pediatric use, is overpriced and presents safety concerns for children. Following the report's publication, Soleno’s stock saw a significant drop, falling by $5.73 per share, which translates to a dip of 7.41%, bringing its closing price down to $71.63 on the same day.

The nature of this investigation raises concerns about the company’s transparency and compliance with regulatory standards, potentially putting investor capital at risk. As a result, Pomerantz LLP is advising members of the investing community to file a report with them, thereby exploring avenues for class-action lawsuits if warranted.

Who is Pomerantz LLP?

Founded by Abraham L. Pomerantz, a pioneer in class action law, Pomerantz LLP boasts over 85 years of experience in defending the rights of investors against corporate misconduct. Headquartered in New York and with additional offices in cities like Chicago, Los Angeles, and various global locations like London and Tel Aviv, the firm specializes in class-action litigations involving securities fraud, fiduciary duty breaches, and corporate malpractice. Their exemplary record includes retrieving substantial damages for class members who have faced losses due to such practices.

Implications for Investors

For investors in Soleno Therapeutics, this situation could have serious implications. If the allegations are substantiated, it may not only affect the company’s stock price further but could result in severe penalties and damages for the company, impacting its long-term viability. Furthermore, ethical questions surrounding the safety of Vykat XR for children could open up more layers of scrutiny regarding its approval and marketing, potentially leading to a larger conflict affecting stakeholders in the pharmaceutical industry.

Next Steps for Concerned Investors

Investors who have incurred losses related to their Soleno investments are encouraged to take proactive steps. Pomerantz LLP is available for consultations and can be reached via email or phone to determine eligibility for participation in any resulting class-action lawsuits. Engaging legal assistance at this juncture could be critical for those looking to recover losses arising from potential deceptive practices by the company.

As the investigation unfolds, both investors and market watchers should keep a vigilant eye on further developments regarding Soleno Therapeutics and any additional insights from Pomerantz LLP. Transparency and integrity in pharmaceutical companies are vital, and this case could serve as a reminder for thorough diligence in investment decisions moving forward.

For more information about joining the class action and possible developments, you can contact Danielle Peyton at Pomerantz LLP via [email protected] or call at 646-581-9980, ext. 7980.